Interaction between CX3CL1 and CX3CR1 regulates vasculitis induced by immune complex deposition.

[1]  H. Deckmyn,et al.  The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib. , 2011, Blood.

[2]  R. Takahashi,et al.  Correlation of CX3CL1 and CX3CR1 Levels with Response to Infliximab Therapy in Patients with Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[3]  P. Murphy,et al.  Chemokine Receptor CX3CR1 Mediates Skin Wound Healing by Promoting Macrophage and Fibroblast Accumulation and Function1 , 2008, The Journal of Immunology.

[4]  L. Becker,et al.  Fractalkine Upregulates Intercellular Adhesion Molecule-1 in Endothelial Cells Through CX3CR1 and the Jak–Stat5 Pathway , 2007, Circulation research.

[5]  D. Patel,et al.  Defective antitumor responses in CX3CR1‐deficient mice , 2007, International journal of cancer.

[6]  Steffen Jung,et al.  The FASEB Journal • Research Communication The neuronal chemokine CX3CL1/fractalkine , 2022 .

[7]  M. Adachi,et al.  Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. , 2005, Arthritis and rheumatism.

[8]  S. Fujita,et al.  Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. , 2005, Arthritis and rheumatism.

[9]  P. Bacon.  Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects , 2005, Current opinion in rheumatology.

[10]  M. Cid,et al.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis , 2004, Current rheumatology reports.

[11]  O. Yoshie,et al.  Fractalkine in Vascular Biology: From Basic Research to Clinical Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[13]  Koichiro Nakamura,et al.  Human keratinocytes express fractalkine/CX3CL1. , 2003, Journal of dermatological science.

[14]  T. Tedder,et al.  Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. , 2003, The American journal of pathology.

[15]  P. Debré,et al.  Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.

[16]  B. McManus,et al.  Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[17]  P. Manow.  ‚The Good, the Bad, and the Ugly‘ , 2002 .

[18]  T. Tedder,et al.  The Cutaneous Reverse Arthus Reaction Requires Intercellular Adhesion Molecule 1 and L-Selectin Expression1 , 2002, The Journal of Immunology.

[19]  J. Köhl,et al.  Distinct Tissue Site-Specific Requirements of Mast Cells and Complement Components C3/C5a Receptor in IgG Immune Complex-Induced Injury of Skin and Lung1 , 2001, The Journal of Immunology.

[20]  S. Lira,et al.  Generation and Analysis of Mice Lacking the Chemokine Fractalkine , 2001, Molecular and Cellular Biology.

[21]  M. Goebeler,et al.  Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.

[22]  J. Köhl,et al.  A Codominant Role of FcγRI/III and C5aR in the Reverse Arthus Reaction1 , 2000, The Journal of Immunology.

[23]  J. Köhl,et al.  On the role of complement and Fc γ-receptors in the Arthus reaction , 1999 .

[24]  P. Clapham,et al.  Chemokine receptors--future therapeutic targets for HIV? , 1999, Biochemical pharmacology.

[25]  J. Westwick,et al.  Chemokines and T lymphocytes: more than an attraction. , 1998, Immunity.

[26]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[27]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[28]  U. Höpken,et al.  Impaired Inflammatory Responses in the Reverse Arthus Reaction Through Genetic Deletion of the C5a Receptor , 1997, The Journal of experimental medicine.

[29]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[30]  T. Standiford,et al.  "The good, the bad, and the ugly." The role of chemokines in models of human disease. , 1996, Journal of immunology.

[31]  J. Ravetch,et al.  Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. , 1994, Science.

[32]  B. Jakschik,et al.  Augmentation of reverse arthus reaction by mast cells in mice. , 1991, The Journal of clinical investigation.

[33]  Y. Miwa,et al.  Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. , 2009, Clinical and experimental rheumatology.

[34]  A. Amadori,et al.  C and CX3C chemokines: cell sources and physiopathological implications. , 2004, Critical reviews in immunology.

[35]  In-kyu Lee,et al.  Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. , 2004, The American journal of pathology.

[36]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[37]  S. Akira,et al.  Interleukin-6 in biology and medicine. , 1993, Advances in immunology.

[38]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.